Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume – Should You Buy?

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) saw unusually-high trading volume on Thursday . Approximately 6,139 shares were traded during mid-day trading, a decline of 27% from the previous session’s volume of 8,428 shares.The stock last traded at $17.69 and had previously closed at $17.15.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on PHAR. Zacks Research raised shares of Pharming Group from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 6th. Weiss Ratings downgraded Pharming Group from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $30.00.

Pharming Group Stock Up 0.6%

The company has a market cap of $1.18 billion, a price-to-earnings ratio of -1,748.25 and a beta of 0.03. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.39 and a current ratio of 3.16. The business’s 50 day simple moving average is $14.45 and its 200-day simple moving average is $12.21.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, November 6th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.05. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%. The business had revenue of $97.30 million for the quarter, compared to analyst estimates of $98.22 million. Pharming Group has set its FY 2025 guidance at EPS. Sell-side analysts expect that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current year.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its holdings in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) by 8.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,147 shares of the company’s stock after purchasing an additional 4,150 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.08% of Pharming Group worth $557,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.